13 hours ago
Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference
SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in a panel discussion and corporate presentation at the H.C. Wainwright Annual Ophthalmology Virtual Conference on August 13, 2025. Details of the presentations are as follows:
7:00 am ET, on-demand corporate presentation
11:00 am ET, 'Pivotal-Stage Assets for Retinal Disorders' panel discussion
Webcast Link InstructionsA webcast of each presentation can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: The replays will be archived for 90 days following the presentation date.
About Belite BioBelite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite's lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at
Media and Investor Relations Contact:Jennifer Wu ir@
Julie Fallonbelite@
